RPS25 Antibody

What is RPS25 and what is its function in cellular biology?

RPS25 (ribosomal protein S25) is a crucial component of the 40S ribosomal subunit involved in protein translation. It functions as part of the cellular machinery responsible for translating genetic information into proteins . Beyond its canonical role in translation, RPS25 has been identified as a novel MDM2 interacting protein that may be involved in p53-mediated apoptosis and cell-cycle arrest . Research has also revealed its potential involvement in viral replication processes for Dicistroviridae and hepatitis C viruses . The protein has a calculated molecular weight of 14 kDa but is typically observed at 15-17 kDa in experimental conditions, likely due to post-translational modifications .

When designing experiments with RPS25 antibodies, appropriate controls are essential for ensuring result validity. For Western blot applications, include positive control samples such as A549, HeLa, K-562, or MCF-7 cell lysates, which have been confirmed to express detectable levels of RPS25 . For negative controls, consider using RPS25 knockout cell lines as demonstrated in the C9orf72 studies , or samples treated with RPS25-targeting siRNA to confirm antibody specificity.

For immunohistochemistry and immunofluorescence, include technical controls such as secondary antibody-only staining to assess background, and biological controls such as tissues known to express varying levels of RPS25. When evaluating antibody specificity, peptide competition assays can be performed by pre-incubating the antibody with the immunizing peptide before application to samples .

How does RPS25 contribute to RAN translation in neurodegenerative diseases?

Recent research has identified RPS25 as a critical factor in repeat-associated non-AUG (RAN) translation, a process implicated in several neurodegenerative diseases . In C9orf72-related amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), hexanucleotide (GGGGCC) repeat expansions undergo RAN translation to produce toxic dipeptide repeat proteins (DPRs) . Studies have shown that knockout or reduction of RPS25 significantly decreases the production of these toxic DPRs without affecting the levels of repeat RNA or RNA foci formation .

Specifically, RPS25 knockout resulted in approximately 50% reduction in poly(GP) levels and over 90% reduction in Glycine-Alanine (GA) frame products from C9orf72 repeat expansions . This effect was also observed with CAG repeat expansions in ATXN2 and HTT genes, suggesting RPS25 plays a broadly important role in RAN translation across different repeat expansion disorders . Importantly, RPS25 appears selective for RAN translation, as its knockout only mildly affected polysome profiles and did not significantly impair global translation .

What methodological approaches can detect alterations in RPS25 expression levels?

Several methodological approaches can be employed to accurately measure RPS25 expression levels:

• Quantitative Western Blotting: Using validated RPS25 antibodies at appropriate dilutions (1:2000-1:10000), researchers can quantify protein levels relative to housekeeping controls . For accurate quantification, standard curves with recombinant RPS25 protein can be established.

• RT-qPCR Analysis: As demonstrated in the C9orf72 studies, RT-qPCR can be used to measure RPS25 mRNA levels, particularly in polysome fractions to assess translation efficiency .

• Immunofluorescence with Digital Quantification: Using standardized protocols with dilutions of 1:20-1:200, followed by digital image analysis to quantify fluorescence intensity .

• Ribosome Profiling: This technique can assess RPS25 incorporation into ribosomes and its impact on translation of specific mRNAs, as suggested by the polysome profile analyses in RPS25 knockout cells .

How do I troubleshoot non-specific binding when using RPS25 antibodies in Western blot applications?

Non-specific binding in Western blot applications using RPS25 antibodies can be addressed through several optimization strategies:

• Optimize Antibody Dilution: Start with manufacturer-recommended dilutions (1:2000-1:10000 for Western blot) and perform a dilution series to identify optimal signal-to-noise ratio .

• Blocking Optimization: Test different blocking agents (BSA, non-fat milk, commercial blockers) at varying concentrations to minimize non-specific binding. For RPS25 antibodies, 5% non-fat milk in TBST is often effective .

• Wash Protocol Modification: Increase washing stringency by extending wash times or adding low concentrations of detergent (0.1-0.3% Tween-20) to remove non-specifically bound antibodies.

• Sample Preparation: Ensure complete denaturation of samples by adjusting boiling time and SDS concentration, as RPS25's ribosomal location may require more stringent denaturation conditions.

• Validation Controls: Include knockout or knockdown samples as negative controls to identify true RPS25 bands versus non-specific signals .

If non-specific binding persists, consider using alternative RPS25 antibodies raised against different epitopes, as some regions may be more prone to cross-reactivity with other ribosomal proteins.

How can RPS25 antibodies be used to investigate neurodegenerative disease mechanisms?

RPS25 antibodies serve as valuable tools for investigating mechanisms underlying neurodegenerative diseases, particularly those involving nucleotide repeat expansions like C9orf72-related ALS/FTD . Specific research applications include:

• Assessing RPS25 Expression Levels: Using validated RPS25 antibodies (1:2000-1:10000 for Western blot), researchers can quantify RPS25 expression in patient-derived samples compared to controls .

• Co-localization Studies: Immunofluorescence approaches using RPS25 antibodies (1:20-1:200) can determine if RPS25 co-localizes with disease-related proteins or RNA foci in patient tissues or cellular models .

• Therapeutic Target Validation: Following RPS25 knockdown or inhibition, antibodies can confirm reduction of RPS25 protein levels when evaluating therapeutic interventions targeting RPS25-dependent RAN translation .

• Monitoring Disease Progression: IHC studies (antibody dilutions 1:50-1:500) of post-mortem tissues can assess whether RPS25 expression or localization changes correlate with disease progression or severity .

• Mechanistic Studies: RPS25 antibodies can help determine if RPS25 directly interacts with repeat-containing mRNAs through immunoprecipitation followed by RNA sequencing .

These approaches collectively enable researchers to explore RPS25's role in pathogenic RAN translation and evaluate the potential of RPS25-targeting strategies for therapeutic development.

What experimental models have been validated for studying RPS25's role in repeat expansion disorders?

Multiple experimental models have been validated for investigating RPS25's role in repeat expansion disorders, each offering distinct advantages:

• Cell Line Models:

  • Hap1 RPS25 knockout cells transfected with repeat constructs demonstrated reduced RAN translation products

  • HeLa cells with reduced RPS25 showed decreased poly(A) RAN products from unmodified HTT CAG repeats

• Patient-Derived Models:

  • iPSCs from ALS patients with C9orf72 repeat expansions treated with RPS25 siRNA showed reduced poly(GP) levels

  • iPSC-derived induced motor neurons (iMNs) from C9orf72 ALS patients demonstrated the effects of RPS25 inhibition on DPR production

• Drosophila Models:

  • Flies expressing 36 GGGGCC repeats with RpS25 knockdown showed reduced poly(GP) levels and significantly increased lifespan

  • Control experiments with flies expressing ATG-driven 36GR repeats demonstrated specificity of the RpS25 effect for RAN translation

Each model system revealed consistent findings regarding RPS25's role in RAN translation, with the combination of approaches providing robust cross-validation of results. The patient-derived models particularly offer clinically relevant contexts for studying RPS25-targeting therapeutic strategies.

How can RPS25 knockdown experiments be designed and validated using RPS25 antibodies?

Designing and validating RPS25 knockdown experiments requires careful planning and proper controls:

• Knockdown Approach Selection:

  • siRNA/shRNA: Transient or stable knockdown using target sequences validated for RPS25

  • CRISPR/Cas9: Complete knockout, as used in Hap1 RPS25 knockout cell lines

  • Antisense oligonucleotides (ASOs): Potentially more therapeutically relevant approach

• Knockdown Validation:

  • Western Blot: Using RPS25 antibodies (1:2000-1:10000) to confirm protein level reduction

  • RT-qPCR: Confirming mRNA level reduction as a complementary approach

• Control Experiments:

  • Non-targeting siRNA/shRNA controls or CRISPR non-cutting controls

  • Rescue experiments reintroducing RPS25 to confirm specificity of observed effects

  • Testing effects on canonical translation using ATG-driven reporters, as performed in the C9orf72 studies

• Functional Validation:

  • Polysome profiling to assess global translation effects after RPS25 knockdown

  • Measurement of specific RAN translation products (e.g., poly(GP), poly(GA)) using appropriate assays

  • Assessment of relevant cellular phenotypes (e.g., toxicity, stress response)

Proper validation using RPS25 antibodies is crucial, as it ensures observed phenotypes are directly linked to successful RPS25 reduction rather than off-target effects.

What are the optimal storage and handling conditions for RPS25 antibodies?

Proper storage and handling of RPS25 antibodies is essential for maintaining their reactivity and specificity:

For optimal handling during experiments, thaw RPS25 antibodies on ice, briefly centrifuge before opening to collect liquid at the bottom of the tube, and always use clean pipette tips to avoid contamination. When preparing working dilutions, use freshly prepared buffers and consider adding protease inhibitors if storing diluted antibody solutions .

How do I optimize RPS25 antibody protocols for different tissue and cell types?

Optimizing RPS25 antibody protocols for various tissue and cell types requires systematic adjustment of several parameters:

• Western Blot Optimization:

  • For different cell lines, adjust lysis conditions to ensure complete extraction of ribosome-associated RPS25

  • Validated in multiple cell types including A549, HeLa, K-562, MCF-7, and Jurkat cells

  • Adjust antibody concentration within the 1:200-1:10000 range based on RPS25 expression levels in your specific sample

• Immunohistochemistry (IHC) Optimization:

  • For different tissue types, test both TE buffer pH 9.0 and citrate buffer pH 6.0 for antigen retrieval

  • Successfully applied to human breast cancer tissue and human liver tissue at dilutions of 1:50-1:500

  • Adjust incubation times and temperatures based on tissue thickness and fixation method

• Immunofluorescence/ICC Optimization:

  • For adherent vs. suspension cells, modify fixation protocols (4% paraformaldehyde vs. methanol fixation)

  • Successfully applied to MCF-7 cells at dilutions of 1:20-1:200

  • Consider detergent concentrations for permeabilization based on subcellular localization

• Sample-Specific Considerations:

  • For tissues with high autofluorescence, incorporate quenching steps in IF protocols

  • For highly vascularized tissues, extend blocking steps to reduce background

  • For samples with low RPS25 expression, consider signal amplification methods

Starting with validated protocols for similar sample types and systematically adjusting parameters will yield optimal results across diverse experimental systems.

How can I differentiate between specific and non-specific signals when using RPS25 antibodies in immunofluorescence?

Differentiating between specific and non-specific signals in immunofluorescence experiments with RPS25 antibodies requires rigorous controls and optimization:

• Positive and Negative Controls:

  • Include known positive samples (e.g., MCF-7 cells) that have been validated for RPS25 detection

  • Use RPS25 knockdown/knockout samples as negative controls when available

  • Include secondary antibody-only controls to assess background fluorescence

• Signal Validation Approaches:

  • Perform peptide competition assays by pre-incubating the antibody with the immunogen peptide

  • Compare staining patterns with multiple RPS25 antibodies raised against different epitopes

  • Correlate with other detection methods (e.g., RPS25 mRNA detection by FISH)

• Technical Optimization:

  • Test a range of antibody dilutions (1:20-1:200) to identify optimal signal-to-noise ratio

  • Optimize blocking conditions using different blocking agents and concentrations

  • Adjust washing stringency to reduce background without compromising specific signal

• Expected Signal Characteristics:

  • RPS25 typically shows cytoplasmic localization with enrichment in ribosome-rich regions

  • The staining pattern should be consistent with ribosomal distribution (primarily cytoplasmic)

  • Co-localization with other ribosomal markers can confirm specificity

By implementing these strategies, researchers can confidently differentiate between specific RPS25 signals and non-specific background, leading to more reliable immunofluorescence results.

How can RPS25 antibodies be applied in studying its role as a potential therapeutic target?

RPS25 antibodies can be instrumental in exploring its potential as a therapeutic target, particularly in repeat expansion disorders:

• Target Validation Studies:

  • Using RPS25 antibodies (1:2000-1:10000 for Western blot) to confirm knockdown efficiency in therapeutic validation studies

  • Quantifying RPS25 levels across different tissues to assess target accessibility and expression variability

• Mechanism of Action Studies:

  • Employing immunoprecipitation with RPS25 antibodies to identify interaction partners that could be alternative therapeutic targets

  • Using immunofluorescence (1:20-1:200) to track changes in RPS25 localization following experimental therapeutic interventions

• Pharmacodynamic Biomarker Development:

  • Developing immunoassays with RPS25 antibodies to monitor RPS25 levels or activity as potential biomarkers of therapeutic efficacy

  • Validating RPS25-associated pathways that could serve as readouts for target engagement

• Therapeutic Efficacy Assessment:

  • Measuring RPS25-dependent RAN translation products (e.g., poly(GP)) following therapeutic intervention

  • Correlating RPS25 levels with disease phenotypes in patient-derived models using immunohistochemistry (1:50-1:500)

The research demonstrating that RPS25 reduction mitigates neurodegenerative phenotypes in fly models of C9orf72 repeat expansion suggests that this approach has genuine therapeutic potential . RPS25 antibodies provide essential tools for advancing this promising therapeutic strategy from concept to clinical application.

What is known about the specificity of different RPS25 antibody clones for experimental applications?

Different RPS25 antibody clones exhibit varying specificities and performance characteristics across experimental applications:

• Epitope Targeting and Specificity:

  • Antibodies raised against full-length RPS25 (e.g., 23599-1-AP) may recognize multiple epitopes, potentially increasing sensitivity but with higher risk of cross-reactivity

  • Antibodies targeting specific peptide sequences (e.g., CAB15314, which targets a sequence within amino acids 50 to the C-terminus) offer more defined epitope recognition

• Application-Specific Performance:

  • Western Blot: Most antibodies detect RPS25 at the expected molecular weight of 15-17 kDa, with some showing minor additional bands that may represent post-translational modifications

  • IHC/IF: Performance varies by fixation method and antigen retrieval protocol, with some antibodies requiring TE buffer pH 9.0 for optimal results

• Cross-Reactivity Profiles:

  • Species cross-reactivity: While all reported antibodies react with human RPS25, reactivity with mouse and rat varies between clones

  • Within-family cross-reactivity: Potential cross-reactivity with other ribosomal proteins should be evaluated, especially when studying closely related family members

• Validation Extent:

  • Some antibodies have been validated in multiple applications (WB, IHC, IF, ELISA) across diverse cell lines

  • Others have more limited validation but may offer superior performance in specific applications

When selecting an RPS25 antibody, researchers should consider the specific requirements of their experimental system and the validation extent of available antibodies. For critical experiments, testing multiple antibody clones may be advisable to confirm findings.

How does RPS25 expression vary across different tissues and disease states?

RPS25 expression patterns show important variations across tissues and disease states that may have functional and clinical significance:

• Tissue-Specific Expression:

  • RPS25 antibodies have detected expression in multiple human tissues including liver and breast cancer tissue

  • In mouse models, expression has been documented in liver and pancreas tissues

  • Cellular expression has been confirmed in multiple cell lines including A549, HeLa, K-562, MCF-7, Jurkat, A431, and BxPC-3 cells

• Disease-Associated Expression Changes:

  • Overexpression in human leukemia cells with adriamycin resistance suggests a potential role in chemotherapy resistance mechanisms

  • The role of RPS25 in RAN translation indicates its functional importance in neurodegenerative diseases like ALS and FTD

  • Potential involvement in p53-mediated apoptosis and cell-cycle arrest suggests relevance to cancer biology

• Functional Implications:

  • Tissue-specific expression patterns may affect the vulnerability of different cell types to repeat expansion disorders

  • Differential expression in disease states may provide insights into pathogenesis and potential therapeutic approaches

  • The involvement in viral replication suggests tissue-specific roles in infection response

• Methodological Considerations:

  • When studying tissue-specific expression, antibody dilutions may need adjustment based on expression levels

  • For Western blot, 1:2000-1:10000 dilutions are recommended, with adaptation based on signal strength

  • For IHC, 1:50-1:500 dilutions are suggested, with tissue-specific optimization

Understanding these expression patterns can inform both basic research into RPS25 function and translational studies targeting RPS25 in disease contexts.